Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres
Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case rep...
Gespeichert in:
Veröffentlicht in: | Clinical and experimental dermatology 2023-11, Vol.48 (12), p.1376-1378 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case reports seem to point not only at its beneficial effects but also at a possible pathogenetic role in mycosis fungoides and Sézary syndrome. We present data collected from a cohort of 995 patients with classic or prurigo nodularis-like AD who received dupilumab and were followed longitudinally for a mean period of 25.1 months after first administration to investigate a possible correlation between dupilumab and CTCL development. |
---|---|
ISSN: | 0307-6938 1365-2230 |
DOI: | 10.1093/ced/llad277 |